In adults with obesity and prediabetes, tirzepatide 5 mg reduced body weight more than placebo at 176 weeks.
In plain wordsIn adults with obesity and prediabetes, 5 mg of tirzepatide led to more weight loss than placebo after 176 weeks.
- Peptide
- Tirzepatide
- Outcome
- DecreasePercent change in body weight at week 176 (5 mg)
- Study
n = 1,032
- Comparator
- Placebo
- Analysis
- Secondary
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- 5 mg once weekly · 176 weeksAs given in this study (human).
Measurements
- percent change in body weight
- −12.3%
- tirzepatide 5 mg
- percent change in body weight
- −1.3%
- placebo
Source sentences
At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).
2 context sentences(design, population, supporting numbers)
We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo.
The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period.